| scholarly article | Q13442814 |
| P356 | DOI | 10.1017/S1744133118000051 |
| P698 | PubMed publication ID | 29576025 |
| P50 | author | Martin McKee | Q17146579 |
| Zoltan Kalo | Q43130291 | ||
| Piotr Ozierański | Q84701905 | ||
| P2093 | author name string | András Harsányi | |
| Lawrence King | |||
| Marcell Csanádi | |||
| Olga Löblová | |||
| P2860 | cites work | Similarities and differences between stakeholders' opinions on using Health Technology Assessment (HTA) information across five European countries: results from the EQUIPT survey. | Q27303775 |
| Attempt to increase the transparency of fourth hurdle implementation in Central-Eastern European middle income countries: publication of the critical appraisal methodology | Q31100143 | ||
| REVIEWING TRANSFERABILITY IN ECONOMIC EVALUATIONS ORIGINATING FROM EASTERN EUROPE | Q36778705 | ||
| Assessing the impact of health technology assessment in The Netherlands | Q37207393 | ||
| HTA Implementation Roadmap in Central and Eastern European Countries. | Q37343970 | ||
| A review of Health Technology Assessment (HTA) recommendations for drug therapies issued between 2007 and 2009 and their impact on policymaking processes in Poland | Q37884876 | ||
| Pharmaceutical lobbying under postcommunism: universal or country-specific methods of securing state drug reimbursement in Poland? | Q37912288 | ||
| Improving the contribution of regulatory assessment reports to health technology assessments--a collaboration between the European Medicines Agency and the European network for Health Technology Assessment | Q38240272 | ||
| CURRENT ENVIRONMENT FOR INTRODUCING HEALTH TECHNOLOGY ASSESSMENT IN GREECE. | Q38653124 | ||
| Three worlds of health technology assessment: explaining patterns of diffusion of HTA agencies in Europe | Q38670095 | ||
| VISIONS OF STAKEHOLDERS ABOUT INSTUTIONALIZATION OF HEALTH TECHNOLOGY ASSESSMENT IN CHILE: A QUALITATIVE STUDY. | Q38735782 | ||
| The transparency of published health technology assessment-based recommendations on pharmaceutical reimbursement in Poland | Q38791269 | ||
| CURRENT IMPLEMENTATION OF HEALTH TECHNOLOGY ASSESSMENT IN HEALTHCARE SYSTEM IN SLOVENIA. | Q38824476 | ||
| The use of non-economic criteria in pricing and reimbursement decisions in Central and Eastern Europe: issues, trends and recommendations | Q38911200 | ||
| Relating Health Technology Assessment recommendations and reimbursement decisions in Poland in years 2012-2014, a retrospective analysis. | Q39059930 | ||
| The development of health technology assessment | Q40609026 | ||
| Priority setting for health technology assessment. Theoretical considerations and practical approaches. Priority setting Subgroup of the EUR-ASSESS Project | Q41508192 | ||
| Health technology assessment in Poland, the Czech Republic, Hungary, Romania and Bulgaria. | Q43926933 | ||
| The impact of health technology assessment reports on decision making in Austria | Q46208860 | ||
| Assessing the impact of health technology assessment on the Austrian healthcare system | Q46883520 | ||
| Who's afraid of institutionalizing health technology assessment (HTA)?: Interests and policy positions on HTA in the Czech Republic | Q47376414 | ||
| HEALTH TECHNOLOGY ASSESSMENT IN CENTRAL, EASTERN, AND SOUTH EUROPEAN COUNTRIES: CROATIA. | Q47743617 | ||
| Multicriteria decision analysis in the reimbursement of new medical technologies: real-world experiences from Hungary | Q48072255 | ||
| OVERVIEW ON THE CURRENT IMPLEMENTATION OF HEALTH TECHNOLOGY ASSESSMENT IN THE HEALTHCARE SYSTEM IN HUNGARY. | Q48661171 | ||
| What has health technology assessment ever done for us? | Q49862558 | ||
| Issues for countries considering introducing the "fourth hurdle": the case of Hungary | Q50141942 | ||
| Transparency vs. closed-door policy: do process characteristics have an impact on the outcomes of coverage decisions? A statistical analysis | Q50186387 | ||
| Assessing the impact of health technology assessment | Q50189020 | ||
| The persistence of cliques in the post-communist state. The case of deniability in drug reimbursement policy in Poland | Q50209391 | ||
| History of health technology assessment in Hungary. | Q53102279 | ||
| What aspects of the health technology assessment process recommended by international health technology assessment agencies received the most attention in Poland in 2008? | Q53160207 | ||
| The politics of health technology assessment in Poland | Q57763644 | ||
| Governing drug reimbursement policy in Poland: The role of the state, civil society, and the private sector | Q59612482 | ||
| Role of health technology assessment in the process of implementation of the EU Transparency Directive: relevant experience from Central Eastern European countries | Q84588632 | ||
| HTA in Central and Eastern European countries; the 2001: A Space Odyssey and efficiency gain | Q87875802 | ||
| Capacity Building for HTA Implementation in Middle-Income Countries: The Case of Hungary | Q88495545 | ||
| P921 | main subject | confidentiality | Q2476929 |
| P304 | page(s) | 1-20 | |
| P577 | publication date | 2018-03-26 | |
| P1433 | published in | Health Economics, Policy and Law | Q15766164 |
| P1476 | title | When health technology assessment is confidential and experts have no power: the case of Hungary. |
Search more.